top of page

Transforming healthcare for people living with chronic conditions.

Introducing Kitea: the world's most accurate implantable sensor for heart failure and hydrocephalus.

Pressure-guided management of chronic disease.

Kitea enables early intervention and delivers better outcomes at every level, through the next generation of micro-implantable devices.

Dr Sarah-Jane Guild
World inside Wand

26 million people worldwide are in heart failure.

A complex disease, heart failure carries an annual global economic burden of US $108 billion.

Today's treatment barriers are failing patients.

Hospitalisation for heart failure often occurs when the patient presents with symptoms of clinical congestion. By this stage, patients may already be in early-stage heart failure.

Heart Health

Treatment is reactive

Assessment of deterioration is complex and expensive

Do not conform to schedules

Deterioration in cardiac function occurs randomly

Significant risks

Delayed treatment can lead to a cascade of disease progression

Requires hospital admission

Patients spend valuable time in hospital away from family

Digital heart inside the Kitea Wand

Heart failure: by the numbers

Percentage of healthcare costs attributed to post-symptomatic hospital admissions

Estimated reduction in hospitalisation rate in year following Kitea implantation

Estimated reduction in healthcare costs through application of Kitea device

How it works

The Kitea system eliminates guesswork by enabling pressure monitoring at home and in hospital, for the first time.
Pressure Sensor

Device is implanted during a simple procedure, designed for long-term use

Measure with Kitea System

Take pressure measurements in hospital or at home, and track symptoms


Physicians monitor measurements and set thresholds for portal notifications


Physicians make informed decisions based on real pressure values

Hydrocephalus: from reactive to proactive care.

Caused by a buildup of excess fluid in the brain, hydrocephalus is a serious, lifelong condition.

The condition disproportionately affects children, and it is generally fatal without treatment. The main treatment path places a shunt in the brain to drain excess fluid and prevent a rise in pressure.

Shunt failure is common

Highest failure rate of any implanted medical device

Symptoms are confusing

Shunt failure can mimic common illnesses

Significant risks

Increase in intracranial pressure can be life threatening

Requires hospital admission

Assessment of failure is complex and expensive

A better way with Kitea.

Improving outcomes at every level.

Surgeons In surgery

For patients

  • Reduced inequity in healthcare access

  • Monitor symptoms any time, any place

  • Early detection, less time in hospital

For hospitals
  • Estimated 30% reduction in costs

  • Fewer CT, MRI and other imaging procedures

  • Better clinical outcomes

For payers
  • Significant reduction in insurance costs

  • Better outcomes for patients

  • Reimbursement codes available for remote monitoring

Our partners

Contact the team.

Thanks, we received your message!

Sources: Heart failure

1. Malik A, Brito D, Vaqar S, et al. Congestive Heart Failure. [Updated 2022 Nov 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan

2. Urbich, M., Globe, G., Pantiri, K. et al. A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014–2020). PharmacoEconomics 38, 1219–1236 (2020).

3. Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Ikonomidis JS, Khavjou O, Konstam MA, Maddox TM, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013; 6:606–619.

4. Angermann CE, Assmus B, Anker SD, et al. Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMSHF). Eur J Heart Fail 2020;22:1891–901.

5. Ambulatory haemodynamic-guided management reduces heart failure hospitalizations in a multicentre European heart failure cohort. Dauw J, Sokolski M, Middleton JT, Nijst P, Dupont M, Forouzan O, Rothman AMK, Ruschitzka F, Flammer AJ, Mullens W.ESC Heart Fail. 2022 Dec;9(6):3858-3867. doi: 10.1002/ehf2.14056. Epub 2022 Aug 2.

Sources: Hydrocephalus

1. Hydrocephalus Association; About Hydrocephalus

2. Simon TD, Riva-Cambrin J, Srivastava R, Bratton SL, Dean JM, Kestle JR; Hydrocephalus Clinical Research Network. Hospital care for children with hydrocephalus in the United States: utilization, charges, comorbidities, and deaths. J Neurosurg Pediatr. 2008 Feb;1(2):131-7.

3. Reddy GK, Bollam P, Caldito G. Long-Term Outcomes of Ventriculoperitoneal Shunt Surgery in Patients with Hydrocephalus. World Neurosurgery. 2014;81(2):404-10.

4. Chern JJ, Macias CG, Jea A, Curry DJ, Luerssen TG, Whitehead WE. Effectiveness of a clinical pathway for patients with cerebrospinal fluid shunt malfunction. Journal of Neurosurgery: Pediatrics. 2010;6(4):318-24

5. Naftel RP, Tubergen E, Shannon CN, Gran KA, Vance EH, Oakes WJ, et al. Parental recognition of shunt failure: a prospective single-institution study. Journal of Neurosurgery: Pediatrics. 2012;9(4):363-71.

6. Barber, J.M., et al., Telemetric intra-cranial pressure monitoring: clinical and financial considerations. British Journal of Neurosurgery, 2017. 31(3): p. 300-306.

bottom of page